Pure Global
NCT06039254

Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function

A Multicenter, Non-randomized, Open-label, Parallel-controlled Study to Evaluate the Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function
Shandong Suncadia Medicine Co., Ltd.·Phase 1·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Chronic Kidney Disease
Drug/Device/Intervention
HRS-1780
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Shandong Suncadia Medicine Co., Ltd.
Timeline & enrollment
Phase
Phase 1
Start date
Sep 01, 2023
End date
Dec 08, 2023
Enrollment
27 participants
Primary outcome

Pharmacokinetics-Cmax,Pharmacokinetics-AUC0-last,Pharmacokinetics-AUC0-inf

Summary

This is a multicenter, non-randomized, open-label, parallel-controlled study. The main
 objective is to evaluate the safety and pharmacokinetics of HRS-1780 in subjects with mild
 and moderate renal impairment versus healthy subjects, and to provide a basis for dose
 selection of HRS-1780 in patients with chronic kidney disease.

ICD-10 classifications
Chronic kidney diseaseChronic kidney disease, unspecifiedChronic kidney disease, stage 1Chronic kidney disease, stage 4Chronic kidney disease, stage 2
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06039254
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06039254 through Pure Global AI's free database. This Phase 1 trial is sponsored by Shandong Suncadia Medicine Co., Ltd. and is currently Not yet recruiting. The study focuses on Chronic Kidney Disease. Target enrollment is 27 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.